Tempus AI Expands Rare Cancer Research and Validates ECG-AF Tool Amid Stock Market Gains
Tempus AI Inc. (NASDAQ: TEM) announced on June 25 2026 that it has entered a research collaboration with Angiosarcoma Aw...
Read story →Tag: Tempus Ai
View all →
Tempus AI Sets Clinical Availability for Whole-Genome Sequencing Test Amid Investor Skepticism
Tempus AI Inc. (NASDAQ:TEM) has announced that its first whole‑genome sequencing assay, xH, will be clinically availab...
Read story →